Verekitug Phase 2 Data Shows Significant Asthma Control Improvement, 83% Reduction in Steroid Use for Upstream Bio
UPB sits 17% above its 52-week low of $7.25 on light trading volume (0.1× avg).
Summary
Upstream Bio presented new, positive Phase 2 VIBRANT trial data for its lead candidate, verekitug, demonstrating statistically significant and clinically meaningful improvements in asthma symptom control (ACQ-6 reduction of -0.9, p=0.014). The data also showed an 83% reduction in the need for rescue systemic corticosteroids or CRSwNP surgery in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma. This strong efficacy, coupled with reductions in inflammatory biomarkers and a convenient quarterly dosing interval, significantly de-risks the program for the small-cap biotech. This positive clinical update follows the company's recent Q1 earnings report which highlighted increased R&D spend on the verekitug program. Traders will now watch for the initiation of Phase 3 trials in CRSwNP and severe asthma, which the company is preparing for, as this data strengthens the drug's commercial potential.
At the time of this announcement, UPB was trading at $8.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $462.8M. The 52-week trading range was $7.25 to $33.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.